Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay.

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 days of surgery. SARS-CoV-2 diagnosis was defined as peri-operative (7 days before to 30 days after surgery); recent (1-6 weeks before surgery); previous (≥7 weeks before surgery); or none. Information on prophylaxis regimens or pre-operative anti-coagulation for baseline comorbidities was not available. Postoperative venous thromboembolism rate was 0.5% (666/123,591) in patients without SARS-CoV-2; 2.2% (50/2317) in patients with peri-operative SARS-CoV-2; 1.6% (15/953) in patients with recent SARS-CoV-2; and 1.0% (11/1148) in patients with previous SARS-CoV-2. After adjustment for confounding factors, patients with peri-operative (adjusted odds ratio 1.5 (95%CI 1.1-2.0)) and recent SARS-CoV-2 (1.9 (95%CI 1.2-3.3)) remained at higher risk of venous thromboembolism, with a borderline finding in previous SARS-CoV-2 (1.7 (95%CI 0.9-3.0)). Overall, venous thromboembolism was independently associated with 30-day mortality ). In patients with SARS-CoV-2, mortality without venous thromboembolism was 7.4% (319/4342) and with venous thromboembolism was 40.8% (31/76). Patients undergoing surgery with peri-operative or recent SARS-CoV-2 appear to be at increased risk of postoperative venous thromboembolism compared with patients with no history of SARS-CoV-2 infection. Optimal venous thromboembolism prophylaxis and treatment are unknown in this cohort of patients, and these data should be interpreted accordingly.

Purpose: Various complications, including physical, cognitive, and functional disorders, have been identified in patients discharged and recovered from COVID-19. Pulmonary rehabilitation (PR) can be considered a strategy for these disorders. This study aimed to investigate the effect of respiratory and core stability tele-exercises on pulmonary function and functional capacity in survivors discharged and recovered from COVID-19. Methods: This randomized clinical trial study was performed in Qom Province, Iran, in 2021. Thirty discharged patients voluntarily participated in this study and were randomly divided into two groups of 15 patients. Eventually, 27 patients in two groups of exercise (13 patients) and control (14 patients) completed this study. The exercise group performed respiratory and core stability tele-exercise for 8 weeks. Before and after the exercise program, pulmonary function, including forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, and six-minute walk test (6MWT) were assessed in both groups. Mixed repeated measures test in SPSS software v. 27, was used to compare the mean of pre-test-post-test information of the groups. The significance level for this study was considered 0.05. Results: In the exercise group, a significant improvement was observed in FVC, FEV1, and 6MWT after the intervention (P≤0.05), but no significant difference was observed in the FEV1/FVC ratio (P>0.05). Furthermore, a significant interaction was observed in 6MWD, FVC, FVC (predicted), FEV1, and FEV1 (predicted). However, in FEV1/FVC ratio, no significant interaction was observed between the two groups (P>0.05). Conclusion: The results of the study showed that in the new crisis resulting from persistent complications of COVID-19, respiratory and core stability exercises by the tele-exercise method could be used as a helpful method in the rehabilitation of patients discharged and recovered from COVID-19 disease.

One of the major toxic effects of exposure to ammonia is the resulting pulmonary acute and chronic effects. This study investigated the acute pulmonary effects of exposure to ammonia lower than the recommended threshold limit value (TLV). This cross-sectional study was conducted in 2021 in four chemical fertilizer production industries using ammonia as the main raw material. A total of 116 workers who were exposed to ammonia were investigated. The level of exposure to ammonia was measured by NMAM 6016, and the evaluation of pulmonary symptoms and function parameters was done using the American Thoracic Society and European Respiratory Society protocols in four sessions. The paired-sample t-test, repeated measures test, Chi-square, and Fisher’s exact test were run to analyze the collected data. The prevalence rates of pulmonary symptoms, including cough, dyspnea, phlegm, and wheezing, were 24.14, 17.24, 14.66, and 16.38%, respectively, after one exposure shift. It was observed that all pulmonary function parameters were reduced after one exposure shift to ammonia. The results revealed that the parameters of vital capacity, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), the FEV1/FVC ratio, and peak expiratory flow significantly decreased ( p < 0.05) across four exposure shifts. The findings indicated that exposure to ammonia at concentrations lower than one-fifth of TLV could bring about acute pulmonary effects and reduce pulmonary function parameters, similar to the pattern observed in obstructive pulmonary diseases.

BACKGROUND: Given the coronavirus 2019 (COVID-19) risk, it is essential to develop a comprehensive risk assessment method to manage the risk of the infectious diseases. OBJECTIVE: This study aimed to develop a risk assessment method for infectious diseases focusing on COVID-19. METHOD: This study was based on the fuzzy Delphi method (FDM) and fuzzy analytical hierarchical process (FAHP) in three steps: (a) designing the preliminary risk assessment algorithm by reviewing the literature, (b) corroborating the designed structure based on the majority opinions of the expert panel and assigning scores to different factors according to the Delphi method, and (c) determining the weight of components and their factors based on the FAHP. RESULTS: The COVID-19 risk index (CVRI) was found to be affected by four components and 19 factors. The four components consisted of the probability of getting sick (5 factors), disease severity (4 factors), health beliefs level (3 factors), and exposure rate (6 factors). The identified components and their relevant factors had different weights and effects on the CVIR. The weights of probability, severity, health beliefs level, and exposure rate components were 0.27, 0.20, 0.14, and 0.38, respectively. The CVRI was found to range from 0.54 to 0.82, defined in three levels. CONCLUSION: Given the significant effects of identified components, factors, and parameters on the incidence of COVID-19 on the one hand and using the FDM and FAHP on the other, the proposed method can be considered as an appropriate method for managing the risk of COVID-19 and other infectious diseases.